Dianthus Therapeutics (NASDAQ:DNTH) Shares Up 7.8% – Should You Buy?

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) traded up 7.8% on Monday . The company traded as high as $27.30 and last traded at $27.09. 142,627 shares changed hands during trading, a decline of 51% from the average session volume of 290,740 shares. The stock had previously closed at $25.12.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Raymond James upgraded shares of Dianthus Therapeutics to a “moderate buy” rating in a research note on Thursday, December 12th. Oppenheimer raised their price objective on Dianthus Therapeutics from $48.00 to $52.00 and gave the company an “outperform” rating in a research report on Monday, November 11th. TD Cowen assumed coverage on Dianthus Therapeutics in a research report on Friday, December 20th. They issued a “buy” rating for the company. Finally, HC Wainwright reiterated a “buy” rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a research note on Monday, November 11th. Eight investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $46.43.

Dianthus Therapeutics Stock Performance

The company has a market capitalization of $800.30 million, a PE ratio of -10.82 and a beta of 1.74. The firm has a fifty day simple moving average of $24.72 and a 200-day simple moving average of $26.59.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.15). The company had revenue of $2.17 million during the quarter, compared to analyst estimates of $1.07 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. As a group, research analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Hedge Funds Weigh In On Dianthus Therapeutics

A number of hedge funds have recently bought and sold shares of DNTH. Barclays PLC lifted its holdings in Dianthus Therapeutics by 390.5% during the 3rd quarter. Barclays PLC now owns 41,684 shares of the company’s stock worth $1,141,000 after buying an additional 33,185 shares during the last quarter. Jane Street Group LLC bought a new position in Dianthus Therapeutics during the third quarter worth $556,000. Wellington Management Group LLP acquired a new position in Dianthus Therapeutics in the third quarter worth $1,473,000. State Street Corp raised its holdings in shares of Dianthus Therapeutics by 101.4% during the third quarter. State Street Corp now owns 821,131 shares of the company’s stock worth $22,483,000 after purchasing an additional 413,425 shares during the period. Finally, Point72 Asset Management L.P. lifted its position in shares of Dianthus Therapeutics by 151.3% in the 3rd quarter. Point72 Asset Management L.P. now owns 437,700 shares of the company’s stock worth $11,984,000 after buying an additional 263,500 shares during the last quarter. 47.53% of the stock is currently owned by institutional investors and hedge funds.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.